CoreRx Inc. has completed its previously announced $130 million acquisition of Societal CDMO Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics.
CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. (CoreRx) today announced that it has completed its acquisition of Societal CDMO, Inc. (Societal CDMO) (Nasdaq: SCTL), a contract...
Several months after Societal CDMO launched a restructuring campaign that led to 26 layoffs, the small molecule contract manufacturer has announced it’s being bought by one of its production peers in Florida.
CoreRx Appoints Dan Dobry as Chief Strategy Officer
CoreRx Invests in Drug Development and Manufacturing Technologies and Capabilities
CoreRx Scientific Leadership Team Adds Michael Grass, Ph.D.
CoreRx Inc., a CDMO with formulation, development and GMP manufacturing sites in Clearwater, Florida and San Rafael, California, has appointed Sitakant (S.K.) Chaudhury as chief financial officer and as a member of CoreRx’s Executive Leadership Team.
CoreRx Inc., a CDMO with formulation development, analytical services and GMP manufacturing sites in Clearwater, Florida and San Rafael, California, has added Amber Broadbent, Ph.D. and Scott Bone, M.S. to CoreRx’s Product Development team. Both individuals will be based at CoreRx’s early product development center in San Rafael, CA.
NEW YORK--(BUSINESS WIRE)--An investment consortium led by Signet Healthcare Partners, Bionpharma, Inc and GMS Capital Partners LLC today announced it has formed Pharma Nobis, LLC (the “Company”) to acquire Fagron’s US contract manufacturing business. This business unit, operating from a manufacturing facility in Texarkana, Texas, provides contract manufacturing and private label services for consumer healthcare companies and retailers in the United States. Fagron will retain a 20% interest in the Company. Todd Daviau, co-founder and former President & CEO of CoreRx, a leading pharmaceutical contract development and manufacturing company, was named CEO of Pharma Nobis.